FY2024 Earnings Estimate for Humana Issued By Zacks Research

Humana Inc. (NYSE:HUM) – Analysts at Zacks Research increased their FY2024 earnings per share (EPS) estimates for shares of Humana in a research report issued on Wednesday, November 13th. Zacks Research analyst D. Chatterjee now anticipates that the insurance provider will post earnings per share of $16.04 for the year, up from their prior estimate of $16.01. The consensus estimate for Humana’s current full-year earnings is $15.83 per share. Zacks Research also issued estimates for Humana’s Q1 2025 earnings at $6.37 EPS and Q2 2025 earnings at $6.25 EPS.

Humana (NYSE:HUM) last posted its earnings results on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share for the quarter, topping analysts’ consensus estimates of $3.48 by $0.68. Humana had a return on equity of 13.20% and a net margin of 1.18%. The firm had revenue of $29.30 billion for the quarter, compared to the consensus estimate of $28.66 billion.

Several other equities research analysts also recently weighed in on HUM. JPMorgan Chase & Co. raised their price target on shares of Humana from $332.00 to $396.00 and gave the company a “neutral” rating in a research report on Wednesday, August 21st. Oppenheimer lowered their target price on shares of Humana from $400.00 to $280.00 and set an “outperform” rating on the stock in a research note on Thursday, October 3rd. UBS Group decreased their price objective on shares of Humana from $380.00 to $250.00 and set a “neutral” rating for the company in a report on Friday, October 4th. Truist Financial reduced their price objective on Humana from $400.00 to $260.00 and set a “hold” rating for the company in a research report on Friday, October 11th. Finally, Bank of America raised Humana from an “underperform” rating to a “neutral” rating and raised their target price for the stock from $247.00 to $308.00 in a research report on Wednesday, November 6th. Twenty analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $315.86.

Humana Stock Performance

Shares of HUM opened at $275.67 on Friday. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.67. The stock has a market cap of $33.19 billion, a P/E ratio of 24.42, a P/E/G ratio of 2.29 and a beta of 0.52. The business’s 50 day moving average price is $281.36 and its 200-day moving average price is $331.61. Humana has a 52 week low of $213.31 and a 52 week high of $527.18.

Humana Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be issued a dividend of $0.885 per share. The ex-dividend date of this dividend is Tuesday, December 31st. This represents a $3.54 annualized dividend and a dividend yield of 1.28%. Humana’s dividend payout ratio is presently 31.36%.

Hedge Funds Weigh In On Humana

Several institutional investors and hedge funds have recently bought and sold shares of the company. Mendota Financial Group LLC boosted its stake in shares of Humana by 9.2% in the 2nd quarter. Mendota Financial Group LLC now owns 319 shares of the insurance provider’s stock valued at $119,000 after buying an additional 27 shares during the period. Capital Advisors Ltd. LLC lifted its position in shares of Humana by 17.0% during the 2nd quarter. Capital Advisors Ltd. LLC now owns 213 shares of the insurance provider’s stock worth $80,000 after purchasing an additional 31 shares during the last quarter. CarsonAllaria Wealth Management Ltd. grew its stake in shares of Humana by 111.4% during the second quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider’s stock worth $28,000 after purchasing an additional 39 shares in the last quarter. Moors & Cabot Inc. grew its stake in shares of Humana by 2.5% during the third quarter. Moors & Cabot Inc. now owns 1,639 shares of the insurance provider’s stock worth $519,000 after purchasing an additional 40 shares in the last quarter. Finally, Harbour Investments Inc. increased its holdings in Humana by 10.5% in the second quarter. Harbour Investments Inc. now owns 432 shares of the insurance provider’s stock valued at $161,000 after buying an additional 41 shares during the last quarter. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.